Many of the research activities and projects at our group involve cutting edge high-throughput -OMICS, including genomics, transcriptomics and epigenomics profiling. In close collaboration with the Oslo University Hospital Genomics and Bioinformatics Core Facilities, our group has extensively characterized a large number of preclinical model systems, including over 40 osteosarcoma and liposarcoma cell lines and xenografts, as well as tumour specimens using next-generation sequencing (NGS) and microarray technology. Our preclinical sarcoma panels have been extensively characterized, describing expression profiles for mRNA, non-coding RNA, miRNA, as well as genomic aberrations including mutations, rearrangements and DNA copy number changes and methylation. The molecular data has been further integrated with detailed phenotypic information, support the selection of models to use for specific preclinical investigations.
Further we have established advanced analysis for clinically relevant parameters as mutational signatures, fusion gene identification and functional annotation of mutations. These well-described model systems represent a unique resource to investigate the efficacy of known and novel therapies, and identification of predictive biomarkers for the development of new therapeutic strategies.